Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results
21 Juillet 2009 - 10:30PM
PR Newswire (US)
Wednesday, August 5, 2009 9:00 a.m. EDT PRINCETON, NJ, July 21
/PRNewswire-FirstCall/ -- NUCRYST Pharmaceuticals Corp. invites
analysts and investors to participate in a briefing on Wednesday,
August 5, with David B. Holtz, Interim President Chief Executive
Officer, and Chief Financial Officer, regarding the Company's 2009
second quarter results. The briefing, via conference call, is set
for 9:00 a.m. EDT. To participate, please call the toll-free number
1-800-731-5774. In addition to standard disclosure over wire
services, a news release with the second quarter results will be
posted on the NUCRYST web site prior to the call. To listen to the
call live on the Internet, please go to
http://www.nucryst.com/web_casts.htm. The briefing will be recorded
and available for re-broadcast on demand for seven days by dialing
1-877-289-8525. Callers will need to provide the operator with the
following reservation number: 21309904 followed by the number sign.
An audio file of the call will also be archived on the NUCRYST web
site. About NUCRYST Pharmaceuticals NUCRYST Pharmaceuticals Corp.
(NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes
medical products that fight infection and inflammation using
SILCRYST(TM), its patented atomically disordered nanocrystalline
silver technology. NUCRYST licensed world-wide rights for
SILCRYST(TM) wound care coating products to Smith Nephew plc, which
markets these products in over 30 countries under their
Acticoat(TM) trademark. NUCRYST has developed its proprietary
nanocrystalline silver in a powder form, referred to as NPI 32101,
for use in medical devices and as an active pharmaceutical
ingredient. Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
DATASOURCE: NUCRYST Pharmaceuticals Corp. CONTACT: David Wills,
Gillian McArdle, Investor Relations, NUCRYST Pharmaceuticals Corp.,
(416) 504-8464,
Copyright